Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns Buy Rating from HC Wainwright

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $10.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 464.97% from the company’s previous close.

ZNTL has been the subject of several other reports. Wells Fargo & Company lowered their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Wedbush reiterated a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Finally, UBS Group lowered their price objective on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Zentalis Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $8.24.

Zentalis Pharmaceuticals Stock Down 6.3 %

Shares of ZNTL opened at $1.77 on Monday. The company has a market cap of $126.14 million, a price-to-earnings ratio of -0.71 and a beta of 1.75. Zentalis Pharmaceuticals has a twelve month low of $1.61 and a twelve month high of $16.27. The company has a 50 day moving average of $2.16 and a two-hundred day moving average of $2.93.

Insider Activity at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, insider Ingmar Bruns bought 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 6th. The stock was bought at an average cost of $2.28 per share, for a total transaction of $45,600.00. Following the completion of the transaction, the insider now directly owns 36,629 shares of the company’s stock, valued at approximately $83,514.12. This trade represents a 120.27 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jan Skvarka bought 60,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were acquired at an average price of $1.72 per share, with a total value of $103,200.00. Following the completion of the transaction, the director now directly owns 149,551 shares of the company’s stock, valued at $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZNTL. Corton Capital Inc. purchased a new position in Zentalis Pharmaceuticals in the fourth quarter valued at $32,000. Captrust Financial Advisors purchased a new position in Zentalis Pharmaceuticals in the fourth quarter valued at $33,000. Erste Asset Management GmbH purchased a new position in Zentalis Pharmaceuticals in the third quarter valued at $37,000. Paloma Partners Management Co purchased a new position in Zentalis Pharmaceuticals in the third quarter valued at $37,000. Finally, Prudential Financial Inc. purchased a new position in Zentalis Pharmaceuticals in the fourth quarter valued at $39,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.